Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1995 2
1997 2
1998 1
2001 2
2004 1
2008 1
2009 1
2010 1
2019 4
2020 1
2021 3
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

19 results
Results by year
Filters applied: . Clear all
Page 1
Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
Zurth C, Koskinen M, Fricke R, Prien O, Korjamo T, Graudenz K, Denner K, Bairlein M, von Bühler CJ, Wilkinson G, Gieschen H. Zurth C, et al. Among authors: gieschen h. Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):747-759. doi: 10.1007/s13318-019-00577-5. Eur J Drug Metab Pharmacokinet. 2019. PMID: 31571146 Free PMC article. Clinical Trial.
Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial.
Shore N, Zurth C, Fricke R, Gieschen H, Graudenz K, Koskinen M, Ploeger B, Moss J, Prien O, Borghesi G, Petrenciuc O, Tammela TL, Kuss I, Verholen F, Smith MR, Fizazi K. Shore N, et al. Among authors: gieschen h. Target Oncol. 2019 Oct;14(5):527-539. doi: 10.1007/s11523-019-00674-0. Target Oncol. 2019. PMID: 31571095 Free PMC article. Clinical Trial.
In vivo models and decision trees for formulation development in early drug development: A review of current practices and recommendations for biopharmaceutical development.
Zane P, Gieschen H, Kersten E, Mathias N, Ollier C, Johansson P, Van den Bergh A, Van Hemelryck S, Reichel A, Rotgeri A, Schäfer K, Müllertz A, Langguth P. Zane P, et al. Among authors: gieschen h. Eur J Pharm Biopharm. 2019 Sep;142:222-231. doi: 10.1016/j.ejpb.2019.06.010. Epub 2019 Jun 21. Eur J Pharm Biopharm. 2019. PMID: 31233862 Review.
Metabolism and Mass Balance of the Novel Nonsteroidal Androgen Receptor Inhibitor Darolutamide in Humans.
Taavitsainen P, Prien O, Kähkönen M, Niehues M, Korjamo T, Denner K, Nykänen P, Vuorela A, Jungmann NA, von Bühler CJ, Koskinen M, Zurth C, Gieschen H. Taavitsainen P, et al. Among authors: gieschen h. Drug Metab Dispos. 2021 Jun;49(6):420-433. doi: 10.1124/dmd.120.000309. Epub 2021 Mar 30. Drug Metab Dispos. 2021. PMID: 33785516 Clinical Trial.
19 results